Apricus Biosciences Inc Share Price Nasdaq
Equities
US03832V1098
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-16 | Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding | CI |
05-14 | Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance | MT |
Sales 2022 | - | Sales 2023 | 2.2 172.97 | Capitalization | 13.61M 1.07B |
---|---|---|---|---|---|
Net income 2022 | -73M -5.73B | Net income 2023 | -37M -2.91B | EV / Sales 2022 | - |
Net Debt 2022 | 4.59M 360M | Net Debt 2023 | 11.23M 882M | EV / Sales 2023 | 11,278,476 x |
P/E ratio 2022 |
-0.98
x | P/E ratio 2023 |
-0.18
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.69% |
Latest transcript on Apricus Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Raj Mehra
CEO | Chief Executive Officer | 64 | 31/12/86 |
Director of Finance/CFO | 52 | 31/12/18 | |
Karen Fusaro
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 77 | 31/08/21 | |
Richard Pascoe
CHM | Chairman | 60 | 28/02/13 |
Daniel O'Connor
BRD | Director/Board Member | 59 | 31/12/18 |
1st Jan change | Capi. | |
---|---|---|
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |